Language selection

Search

Details for: VOTRIENT

Company: NOVARTIS PHARMACEUTICALS CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02352303VOTRIENTPAZOPANIB (PAZOPANIB HYDROCHLORIDE)200 MGTABLETORAL
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Summary Safety Review - VOTRIENT (pazopanib) - Assessing the Potential Risk of Accumulation of Fluid Around the Heart (Pericardial Effusion)
Summary Safety Review - Vascular Endothelial Growth Factor Receptor Inhibitors - Thrombotic Microangiopathy

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: